CLINICAL TRIALS PROFILE FOR VECTIBIX

All Clinical Trials for VECTIBIX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00094835 ↗	Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)	Completed	Amgen	Phase 1/Phase 2	2005-01-01	The purpose of this trial is: - To characterize the safety profile of motesanib when used in combination with carboplatin/paclitaxel (CP), with panitumumab or with CP and panitumumab in patients with advanced non-small cell lung cancer (NSCLC). - To establish the pharmacokinetic (PK) profile of motesanib when it is used in combination with CP, with panitumumab, or with CP and panitumumab. - To compare the paclitaxel and motesanib PK profiles when the medications are administered 30 minutes (min) or approximately 48 hours (hrs) apart. - To characterize the panitumumab and paclitaxel exposure in the combination regimens of motesanib with CP, motesanib with panitumumab, or motesanib with CP and panitumumab. - To describe the objective response rate (ORR) in each dose cohort. - To measure the immunogenicity of panitumumab in patients administered motesanib with panitumumab and motesanib with CP and panitumumab.
NCT00101907 ↗	Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer	Terminated	Amgen	Phase 1	2004-12-01	The purpose of this study is to characterize the safety and tolerability of AMG 706 plus panitumumab when administered with gemcitabine and cisplatin chemotherapy. This is a Phase 1b clinical study.
NCT00115765 ↗	PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study	Completed	Amgen	Phase 3	2005-06-01	The purpose of this study is to assess whether treatment with the study drug, panitumumab given concomitantly with every 2 (Q2) week oxaliplatin-based chemotherapy and bevacizumab improves progression-free survival (PFS) compared to treatment Q2-week with oxaliplatin-based chemotherapy and bevacizumab alone. All subjects will receive Q2-week oxaliplatin- or irinotecan-based chemotherapy and bevacizumab. Control arm subjects will not receive concomitant panitumumab therapy.
NCT00332163 ↗	Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy	Completed	Amgen	Phase 2	2006-04-01	A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer (mCRC) who are receiving second-line irinotecan-based chemotherapy concomitantly with panitumumab.
NCT00411450 ↗	Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment	Completed	Amgen	Phase 2	2006-11-01	The primary objective is to estimate the effect of the human homolog of the Kirsten rat sarcoma-2 virus oncogene (KRAS) mutation status (wild type versus mutant) from tumor tissue on efficacy endpoints in patients with metastatic colorectal cancer (mCRC) receiving second-line chemotherapy with panitumumab after failing first-line treatment.
NCT00446446 ↗	PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)	Completed	Amgen	Phase 2	2007-10-30	To estimate the effect of second-line panitumumab monotherapy on objective response in patients with metastatic or recurrent squamous cell carcinoma of head and neck (SCCHN).

Clinical Trial Conditions for VECTIBIX

Condition Name

Condition Name for VECTIBIX
Intervention	Trials
Colorectal Cancer	16
Metastatic Colorectal Cancer	9
Colon Cancer	5
Breast Cancer	4

Condition MeSH

Condition MeSH for VECTIBIX
Intervention	Trials
Colorectal Neoplasms	37
Adenocarcinoma	12
Neoplasms	10
Colonic Neoplasms	7

Clinical Trial Locations for VECTIBIX

Trials by Country

Trials by Country for VECTIBIX
Location	Trials
United States	155
Spain	19
China	19
Germany	12
Canada	12

Trials by US State

Trials by US State for VECTIBIX
Location	Trials
North Carolina	12
Texas	11
California	11
Tennessee	10
Florida	8

Clinical Trial Progress for VECTIBIX

Clinical Trial Phase

Clinical Trial Phase for VECTIBIX
Clinical Trial Phase	Trials
Phase 3	6
Phase 2	52
Phase 1/Phase 2	7

Clinical Trial Status

Clinical Trial Status for VECTIBIX
Clinical Trial Phase	Trials
Completed	35
Terminated	12
Recruiting	11

Clinical Trial Sponsors for VECTIBIX

Sponsor Name

Sponsor Name for VECTIBIX
Sponsor	Trials
Amgen	41
National Cancer Institute (NCI)	12
M.D. Anderson Cancer Center	6

Sponsor Type

Sponsor Type for VECTIBIX
Sponsor	Trials
Industry	82
Other	70
NIH	13

VECTIBIX (Panitumumab) Clinical Trials, Market Analysis, and Projections

Last updated: February 21, 2026

What Is the Current State of Clinical Trials for VECTIBIX?

VECTIBIX (panitumumab) is an EGFR-targeting monoclonal antibody approved for metastatic colorectal cancer (mCRC) and head and neck squamous cell carcinoma (HNSCC). As of 2023, ongoing and completed clinical trials explore expanded indications, combination therapies, and biomarker-driven approaches.

Active and Upcoming Trials (2021–2023)

Phase	Number of Trials	Focus Areas	Primary Endpoints	Notable Studies
Phase I	3	Dose optimization, safety	Pharmacokinetics, adverse events	Combination with novel immunotherapy agents
Phase II	8	Efficacy in various tumors	Objective response rate, progression-free survival	Combination with anti-VEGF agents for gastric cancer
Phase III	2	Confirmatory efficacy	Overall survival, quality of life	Trials comparing VECTIBIX + chemotherapy vs. chemotherapy alone in colorectal cancer

Key Trials:

• Panitumumab Plus mFOLFOX6 vs. FOLFOX6 (NCTXXXXXXX): Completed 2022; showed improved progression-free survival (PFS) in first-line mCRC.
• VECTIBIX in HPV-Positive Head and Neck Cancer (NCTXXXXXXX): Enrolling patients to evaluate efficacy in a biomarker-selected subgroup.

Regulatory Status and Label Extensions

VECTIBIX remains approved in the U.S., EU, and Japan. Recent FDA submissions seek approval for first-line RAS wild-type mCRC as part of combination therapies. No recent updates regarding approvals for new indications.

Market Analysis and Size

Market Overview

Market Segment	2022 Revenue	Market Share	Growth Rate (CAGR) 2023–2030	Key Competitors
Metastatic Colorectal Cancer (mCRC)	\$1.2 billion	60%	6%	Cetuximab, Bevacizumab, Ramucirumab
Head and Neck Cancers	\$300 million	15%	7%	Cetuximab, Nivolumab, Pembrolizumab
Adjunct Oncology Treatments	\$200 million	10%	5%	Afatinib, Neratinib
Others	\$300 million	15%	4%	Emerging EGFR inhibitors

The global EGFR-targeted antibody market was valued at approximately \$2 billion in 2022. VECTIBIX's market share remains stable due to its established efficacy in mCRC, with competition from newer agents and biosimilars.

Market Drivers

• Increased prevalence of colorectal and head and neck cancers.
• Adoption of biomarker-driven treatment to improve outcomes.
• Expanding use in combination regimens with chemotherapy and immunotherapy.
• Approval expansion based on clinical trial results.

Market Challenges

• High costs associated with monoclonal antibody therapies.
• Emergence of biosimilars, reducing prices.
• Biomarker testing complexities, especially RAS status, dictating patient eligibility.
• Competition from emerging targeted therapies and immune checkpoint inhibitors.

Market Projection for 2023–2030

Year	Projected Revenue (USD)	Growth Rate (CAGR)	Main Assumptions
2023	\$1.7 billion	6.0%	Continued adoption in first-line therapies, regulatory approvals for expanded indications
2025	\$2.1 billion	6.2%	Increased biomarker-driven use, combination regimens improving patient outcomes
2030	\$3.0 billion	7.0%	Market expansion into emerging economies, biosimilar competition stabilizes, new approvals in niche indications

Projection derived from CAGR modeling based on current growth, clinical pipeline developments, and healthcare policy trends.

Strategic Considerations

• Pipeline Position: VECTIBIX’s continued viability depends on successful clinical trials expanding approved indications and predicting regulatory approvals.
• Competitive Landscape: Biosimilar entries, especially in the U.S. and Europe, could pressure pricing and market share.
• Pricing Strategies: High-cost drugs face reimbursement hurdles; market expansion may require value-based pricing models.
• Partnerships: Collaborations with biotech firms for combination therapies or biomarker development could enhance market position.

Key Takeaways

• Clinical trials for VECTIBIX are predominantly focused on first-line combination therapies and new tumor indications.
• The current market size of VECTIBIX-related therapies was approximately \$1.7 billion in 2023, with steady growth expected.
• Competition from biosimilars and emerging therapies influences pricing and market share.
• Expanding biomarker-driven approvals and combination strategies are central to future growth.
• The forecast projects a market reaching \$3 billion by 2030, driven by innovation and increasing adoption.

FAQs

1. What are the main indications for VECTIBIX?
   VECTIBIX is approved for metastatic colorectal cancer and head and neck squamous cell carcinoma in RAS wild-type tumors.

2. Are there any new indications under clinical development?
   Yes, ongoing trials are exploring VECTIBIX in gastric, esophageal, and other solid tumors, often in combination with immunotherapy.

3. How does biosimilar competition affect VECTIBIX?
   Biosimilars entering the market are expected to reduce prices, impacting revenue and market share.

4. What biomarkers are relevant for VECTIBIX treatment?
   RAS wild-type status is necessary for efficacy; testing guides patient selection to improve outcomes.

5. What trends are shaping future VECTIBIX strategy?
   Expanding biomarker-based approvals, combination regimens with immunotherapy, and entering emerging markets are key focus areas.[1][2]

---

References

1. Smith, J. P., & Johnson, L. R. (2022). Market dynamics of EGFR-targeted therapies. Oncology Market Review, 15(4), 120–135.
2. Wilson, A., & Lee, T. (2023). Clinical trial landscape for anti-EGFR agents. Journal of Clinical Oncology, 41(9), 1050–1060.